<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02680275</url>
  </required_header>
  <id_info>
    <org_study_id>16</org_study_id>
    <nct_id>NCT02680275</nct_id>
  </id_info>
  <brief_title>Efficacy of Dead Sea Peloid Gel in Chronic Endometritis</brief_title>
  <official_title>Efficacy of Intravaginal Dead Sea Peloid Gel Administration in Complex Treatment of Chronic Endometritis and Reproductive Disorders: Randomized Placebo-controlled Prospective Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Scientific Center for Family Health and Human Reproduction Problems, Russia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Scientific Center for Family Health and Human Reproduction Problems, Russia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the effect of Dead Sea Peloid Gel in the treatment of Chronic
      Endometritis in women with reproductive disorders. Half of participants will receive Dead Sea
      Peloid Gel and antibiotics, while the other half will receive Placebo Gel and antibiotics.

      Patients with reproductive disorders who visited Research Medical Center of Family Health
      Problems and Human Reproduction were recruited.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Dead Sea Peloid Gel achieves improvement of blood circulation and receptor sensitivity of
      endometrium.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2011</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The prevalence of spontaneous pregnancy the first year after treatment</measure>
    <time_frame>during first year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The prevalence of women with morphological status of chronic endometritis by the 3 months after treatment.</measure>
    <time_frame>during 3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Chronic Endometritis</condition>
  <arm_group>
    <arm_group_label>Doxycycline,Dead Sea Peloid Gel,placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group -1 stage: Doxycycline 100mg 2 times per day 10 days; followed by Dead Sea Peloid Gel , 60 ml per day fo 12 days, intravaginally
Group -1 stage: Doxycycline 100mg 2 times per day 10 days; followed by placebo gel, 60 ml per day fo 12 days, intravaginally</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dead Sea Peloid Gel</intervention_name>
    <description>intravaginally</description>
    <arm_group_label>Doxycycline,Dead Sea Peloid Gel,placebo</arm_group_label>
    <other_name>Placebo Gel</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women with miscarriage associated with chronic endometritis

          -  Women without mental disorders able to swallow tablets

        Exclusion Criteria: Clinical diagnosis of:

          -  sexually transmitted diseases

          -  endometrium hyperplasia and/or polyps

          -  uterina fibroids

          -  endocrine disorders

          -  trombophilia
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marina A Darenskaya, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Scientific Center for Family Health and Human Reproduction Problems</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Scientific Center for Family Health and Human Reproduction Problems</name>
      <address>
        <city>Irkutsk</city>
        <zip>664003</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 22, 2015</study_first_submitted>
  <study_first_submitted_qc>February 10, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 11, 2016</study_first_posted>
  <last_update_submitted>February 10, 2016</last_update_submitted>
  <last_update_submitted_qc>February 10, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 11, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Scientific Center for Family Health and Human Reproduction Problems, Russia</investigator_affiliation>
    <investigator_full_name>Irina N. Danusevich</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Chronic endometritis</keyword>
  <keyword>Miscarriage</keyword>
  <keyword>Infertility</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endometritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxycycline</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>The study can generate the publications related to the outcomes. The investigator initiating the protocol (Protocol leader/coPI) will be the first (primary) author of the publication. The publication wil also could involve the names of the site investigators who have contributed to the study. The authorship order of the site investigators will be based upon personal contribution to the study, approved by the SCFHHRP (sponsor). The primary affiliation of the study is SCFHHRP.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

